EW · Edwards Lifesciences Corporation
$81.052026-05-17Sector: Healthcare; Industry: Medical - Devices; Sub-Industry: Health Care Equipment
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Base · active
$52
-36.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($48 · $52) Analysts Range ($87 · $110) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $5.2B | — | 36.6% | 11.7% | $1.7B | −$189MM | $1.5B | 7.1% | — | 22.4% | $7.5B | $2.58 | — |
| 2022.Q4 | $5.4B | 2.9% | 37.6% | 13.9% | $1.7B | −$815MM | $928MM | 8.2% | — | 22.6% | $7.9B | $2.62 | — |
| 2023.Q4 | $5.0B | -6.9% | 33.9% | 11.6% | $1.5B | −$913MM | $587MM | 7.9% | — | 18.5% | $8.4B | $2.41 | — |
| 2024.Q4 | $5.4B | 8.6% | 30.1% | 9.8% | $1.5B | $2.2B | $3.7B | 8.6% | — | 16.4% | $9.6B | $7.18 | — |
| 2025.Q4 | $6.1B | 11.5% | 31.8% | 17.0% | $1.6B | −$368MM | $1.2B | 8.5% | — | 16.5% | $9.8B | $1.84 | 24.5 |
| italics below = DCF projection · 10yr Rev CAGR: 7.9% |
| 2026.Q4 | $6.7B | +10.1% | 32.2% | 17.3% | $1.8B | −$1.0B | $773MM | 8.4% | $713MM | 17.3% | $10.8B | $2.57 | 31.5 |
| 2027.Q4 | $7.3B | +9.8% | 33.8% | 17.6% | $2.0B | −$1.1B | $953MM | 8.4% | $812MM | 18.0% | $11.9B | $2.95 | 27.5 |
| 2028.Q4 | $8.1B | +9.9% | 34.8% | 17.9% | $2.3B | −$1.2B | $1.1B | 8.4% | $847MM | 18.4% | $13.1B | $3.33 | 24.3 |
| 2029.Q4 | $8.9B | +10.1% | 35.6% | 18.2% | $2.6B | −$1.4B | $1.2B | 8.4% | $861MM | 18.7% | $14.5B | $3.74 | 21.7 |
| 2030.Q4 | $9.7B | +8.9% | 35.6% | 18.5% | $2.8B | −$1.4B | $1.4B | 8.4% | $958MM | 18.5% | $15.9B | $4.06 | 20.0 |
|
| Term. Yr+ | $13.5B | 4.1% | 23.2% | 20.0% | $2.5B | −$984MM | $1.5B | 8.6% | $15.0B | 10.4% | — | — | — |
Active scenario IV: $52 (-36.3% vs market)